From the Editor-in-Chief: Where's the Value in These Never-Ending M&As?
BioProcessing Journal · 2026-07-28 · 4
DOI: 10.12665/j124.carson ↗At a glance
Journal article in BioProcessing Journal, published online on 2026-07-28. Written by Keith L. Carson.
Abstract (original language)
I’ve seen little to tell me the major biopharma firms, or the larger supply firms, have learned anything. They’re stuck on the concepts of slashing vital resources—such as R&D and capacity—to “do deals” plus pay executive bonuses, investment bankers, and hordes of attorneys. As a result, we’ve seen a burgeoning of Business-to-Business (B2B) meetings where the talks are geared toward selling companies and acquisition services. So we continue to see these large firms hoarding cash, acquiring companies, and cutting strategic resources...
Cite
APA
Carson, K. L. (2026). From the Editor-in-Chief: Where's the Value in These Never-Ending M&As?. BioProcessing Journal, 4. https://doi.org/10.12665/j124.carson
Vancouver
Carson KL. From the Editor-in-Chief: Where's the Value in These Never-Ending M&As?. BioProcessing Journal. 2026:4. doi:10.12665/j124.carson
BibTeX
@article{Carson2026,
author = {Carson, Keith L.},
title = {From the Editor-in-Chief: Where's the Value in These Never-Ending M&As?},
journal = {BioProcessing Journal},
year = {2026},
pages = {4},
doi = {10.12665/j124.carson}
}
EUVIMED